Abstract:
Objective To assess the role of EGFR mutations on pemetrexed response in patients with advanced lung adenocarcinoma.
Method Forty pulmonary adenocarcinoma patients with evaluable lesions were retrospectively screened.They had been treated with pemetrexed-included chemotherapy and had EGFR gene test results. The evaluation endpoints were overall response rate, disease control rate and progression free survival.
Result No significant statistical difference was seen in overall response rate(ORR)(44.4% VS 31.8%, respectively) and disease control rate(DCR) (88.9% VS 81.8%, respectively) between EGFR wild group and EGFR mutation group, but patients in EGFR wild group had longer progression free survival(PFS) (8.9 months VS 5.3 months; P=0.046).
Conclusion EGFR mutation status can influence the efficacy of pemetrexed.